Topic Hub
6 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 6 of 6 clinical reviews.
Health-economic analysis of the FLOW trial: semaglutide cost per QALY in CKD with type 2 diabetes, payer-coverage gaps, list-price vs net-price realities, and patient-level value calculations.
Read clinical reviewAnalysis of FLOW trial durability signals, post-trial follow-up implications, and long-term safety data for semaglutide in type 2 diabetes with chronic kidney disease.
Read clinical reviewDeep-dive into the FLOW trial's pre-specified and post-hoc subgroup analyses, examining how age, sex, BMI, race/ethnicity, and baseline kidney function influenced semaglutide's renal outcomes in type 2 diabetes with CKD.
Read clinical reviewA plain-English deep dive into the FLOW trial, the first RCT to show semaglutide slows kidney disease progression in people with type 2 diabetes and chronic kidney disease.
Read clinical reviewA critical appraisal of the FLOW trial (semaglutide in T2D with CKD), covering enrollment biases, generalizability gaps, early stopping effects, sponsor involvement, and what post-publication commentary revealed.
Read clinical reviewHow the FLOW trial's kidney outcomes with semaglutide should reshape prescribing for type 2 diabetes with CKD, which guidelines responded, and where evidence gaps remain.
Read clinical review